|Articles|March 3, 2004

ACTion Issue Alert Registration

ACTion Newsletter logo

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

FDA Approves Komzifti for NPM1-Mutated AML Based on Positive Phase I/II KOMET-001 Trial Data

ByAndy Studna, Senior Editor

November 14th 2025

Proactive Planning is Key to Mitigating Study Rescue

ByAshley Daigneau

November 14th 2025

ACT Brief: Site Satisfaction, eSource Data Transfers, and Gilead HIV Trial Results

ByAndy Studna, Senior Editor

November 14th 2025

© Ezume Images - © Ezume Images - stock.adobe.com

Gilead’s Single-Tablet Bictegravi/Lenacapavir Regimen Shows Positive Phase III ARTISTRY-1 Results in Virologically Suppressed Adults with HIV

ByAndy Studna, Senior Editor

November 13th 2025

© tippapatt - © tippapatt - stock.adobe.com

Advarra and IgniteData Partner to Streamline eSource-to-EDC Data Transfer

ByAndy Studna, Senior Editor

November 13th 2025

ACTion Issue Alert Registration

Newsletter

Related Content

FDA Approves Komzifti for NPM1-Mutated AML Based on Positive Phase I/II KOMET-001 Trial Data

Proactive Planning is Key to Mitigating Study Rescue

ACT Brief: Site Satisfaction, eSource Data Transfers, and Gilead HIV Trial Results

Gilead’s Single-Tablet Bictegravi/Lenacapavir Regimen Shows Positive Phase III ARTISTRY-1 Results in Virologically Suppressed Adults with HIV

Advarra and IgniteData Partner to Streamline eSource-to-EDC Data Transfer

Trending on Applied Clinical Trials Online

FDA Approves Komzifti for NPM1-Mutated AML Based on Positive Phase I/II KOMET-001 Trial Data